Human infections caused by flatworms belonging to the class of cestodes and trematodes (e.g., taeniasis, hydatidosis, fascioliasis, schistosomiasis) result in significant morbidity, particularly in underdeveloped and underserved communities. While existing anthelmintic drugs like praziquantel and albendazole are effective against these diseases, they encounter challenges such as limited access issues, recurrent infections, and increasing concerns about drug resistance. This policy brief suggests ways to enhance the utilization of nanoparticles as a targeted drug delivery system, a crucial strategy in public health policy to address these neglected diseases